Effect of probiotic in Parkinson's disease patients
- Conditions
- parkinson.Parkinson's disease
- Registration Number
- IRCT20200921048793N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Age over 18 and under 80
Diagnosis of idiopathic Parkinson's disease based on UK PD Society Brain Bank criteria
Using l-dopa or dopaminergic agonist
Use of systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral)
Use of commercial probiotics: includes tablets, capsules.
Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years
History of active uncontrolled gastrointestinal disorders or diseases including: inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis
Infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated)
Age over 80
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analyses Level of TNF-a, IL-1ß, IL-10, Malondialdehyde (MDA), Total antioxidant capacity (TAC). Timepoint: At the beginning of the study and week 12. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method